Palmitoyl Tripeptide-1 is the tripeptide glycyl-histidyl-lysine (GHK) with a palmitic acid chain bolted onto one end. The fatty-acid tail is the whole point of the modification: plain GHK is water-loving and doesn't cross skin's lipid barrier well, so attaching palmitic acid makes the molecule more oil-soluble and easier to deliver topically. You'll see it called Pal-GHK or palmitoyl oligopeptide, under CAS number 147732-56-7. Its molecular formula is C30H54N6O5 (PubChem CID 10231864).
It is a cosmetic ingredient, not an approved drug. It shows up on skincare labels — most famously as part of Sederma's Matrixyl 3000 complex — and is regulated as a cosmetic, not a medicine. Nothing here is medical or dosing advice.
Where it comes from
The parent peptide, GHK, was identified in human blood plasma in 1973 and also occurs in saliva and urine. Its levels in the body fall with age. GHK is best understood as a matrikine: a small signal fragment released when the skin's extracellular matrix breaks down, which then tells fibroblast cells to start repair work. Palmitoyl Tripeptide-1 is the synthetic, skin-penetrating cosmetic version of that signal.
Worth keeping straight: Pal-GHK is not the same as GHK-Cu, the copper-bound "copper peptide" (INCI name Copper Tripeptide-1). Both are built on the GHK sequence, but Pal-GHK swaps the copper complex for a palmitic acid tail.
Mechanism, as documented
The proposed action is signaling, not structural. Rather than adding collagen to the skin's surface, the peptide is meant to penetrate and prompt fibroblasts in the dermis to make more matrix components themselves.
Most of the detailed mechanistic work in the published literature is on GHK itself, not the palmitoylated derivative. The most-cited reference is a 2015 review by Pickart and colleagues, which documents GHK stimulating both the synthesis and turnover of collagen and glycosaminoglycans, modulating metalloproteinases and their inhibitors, and supporting wound healing across several tissue types (Pickart et al., 2015, *BioMed Research International*). The reasonable inference is that Pal-GHK delivers a GHK signal across the skin barrier, but the heavy mechanistic evidence sits with the parent compound.
What the evidence actually supports
This is where honesty matters. Efficacy data specific to Palmitoyl Tripeptide-1 comes largely from manufacturer testing of finished formulas, not independent peer-reviewed trials of the isolated peptide. Cosmetic-ingredient references that catalog this ingredient note the same gap: the marketed before-and-after numbers (wrinkle-depth reductions, skin-thickness gains) trace back to supplier studies of complexes like Matrixyl 3000, and supplier results "always have to be taken with a pinch of salt" (INCIDecoder).
So the picture is:
- Well-established: the chemistry, the GHK lineage, and a real body of literature on GHK biology.
- Plausible but supplier-dependent: the specific anti-wrinkle and collagen-stimulation claims for Pal-GHK in cosmetic products.
- Thin: large independent clinical trials of Palmitoyl Tripeptide-1 on its own.
On safety, the Cosmetic Ingredient Review panel has assessed palmitoyl oligopeptides as used in cosmetics; that document is the relevant reference point for topical-use safety (CIR safety assessment, palmitoyl oligopeptides).
The buyer angle: identity and purity
Because peptides are easy to mislabel and hard to eyeball, the question that matters for a raw-material or research-grade purchase isn't the marketing — it's whether the vial contains what the label says, at the stated purity. That means asking for a certificate of analysis with identity confirmation (mass spec) and purity (HPLC) tied to the specific lot, not a generic spec sheet. Products sold as research chemicals are labeled research use only and not for human consumption; treat that labeling as load-bearing.
peptideone aggregates the independent quality and reputation signals it collects on vendors so identity and purity claims can be compared rather than taken on faith.